Overview

• US biopharma reported Q1 revenue fell sharply year-over-year

• Net loss widened to $8.1 mln from $0.8 mln a year earlier

• Company completed $7 mln direct offering and extended debt maturity to August 2027

Outlook

• Clene expects to submit NDA for CNM-Au8 in Q3 2026 under accelerated approval pathway

• Company plans to start confirmatory Phase 3 trial for CNM-Au8 in Q1 2027

• Clene expects cash runway into Q4 2026, potentially extending into 2027 with warrant exercises

Result Drivers

• R&D EXPENSES DOWN - Lower research and development costs mainly due to decreased ALS program and RESTORE-ALS trial planning expenses, partially offset by higher regulatory and MS program costs

• G&A EXPENSES DOWN - General and administrative expenses fell due to lower personnel, stock-based compensation, legal fees, depreciation, and increased grant revenue

• OTHER EXPENSES UP - Higher other expenses driven by warrant liability issuance costs, one-time loss on equity issuance, and increased interest expense from larger debt balances

Company press release: ID:nGNXBcLRZ

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Clene Inc is $30.00, about 361.5% above its May 13 closing price of $6.50

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.